Exact dates: TBC
Location: Scotland, UK (exact location TBC)

Leucine-Rich Repeat Kinase 2 (LRRK2) is one of the most common genetic contributors to Parkinson’s disease and is also implicated in idiopathic forms. As a multi-domain kinase with diverse cellular functions, LRRK2 has become a leading therapeutic target. With kinase inhibitors, ASOs and PROTACS now in clinical trials and novel approaches advancing, the field is entering a pivotal phase. 

This international meeting will unite academic and industry scientists and clinicians to discuss the latest advances in LRRK2 biology, disease mechanisms, and therapeutic development - from vesicular trafficking and lysosomal function to biomarker discovery and clinical translation. The program will also highlight early-career researchers and foster cross-sector collaboration to accelerate progress for people with Parkinson’s disease. 

Organising committee: 
Sabine Hilfiker, Rutgers University, US 
Esther Sammler, University of Dundee, UK 
Christine Klein, University of Lübeck, Germany
Suzanne Pfeffer, Stanford University, US